SCHEDULE: BlackRock Trims Inhibrx Biosciences Stake Below 5%
Beneficial Ownership Report
BlackRock, Inc. has reported a reduced beneficial ownership in Inhibrx Biosciences, Inc. to 4.7% of common stock.
Summary
- BlackRock, Inc. filed an Amendment No. 1 to Schedule 13G regarding its beneficial ownership in Inhibrx Biosciences, Inc.
- As of September 30, 2025, BlackRock, Inc. beneficially owned 680,368 shares of Inhibrx Biosciences, Inc. common stock.
- This represents 4.7% of the total outstanding common stock, placing BlackRock's aggregate ownership below the 5% threshold.
- BlackRock, Inc. holds sole voting power over 664,427 shares and sole dispositive power over 680,368 shares.
- No shared voting or dispositive power was reported.
- The securities were acquired and are held in the ordinary course of business, not for the purpose of changing or influencing control of the issuer.
Sentiment
Score: 4
Explanation: The filing indicates BlackRock, Inc. has reduced its beneficial ownership in Inhibrx Biosciences, Inc. to 4.7%, falling below the 5% threshold. While not a complete divestment, a reduction by a major institutional investor can be perceived as a slightly negative signal regarding future prospects or a reallocation of capital.
Positives
- NA A Schedule 13G filing primarily discloses ownership and does not typically contain positive operational or financial news for the issuer.
Negatives
- BlackRock, Inc. has reduced its beneficial ownership in Inhibrx Biosciences, Inc. to 4.7%, falling below the 5% reporting threshold, which may be interpreted as a decrease in institutional conviction.
Risks
- NA This filing does not detail specific risks for the issuer, Inhibrx Biosciences, Inc.
Future Outlook
NA This filing does not provide any forward-looking statements or guidance for Inhibrx Biosciences, Inc.
Industry Context
NA This filing does not provide analysis of broader industry trends or competitors for Inhibrx Biosciences, Inc.
Comparison to Industry Standards
- NA This filing does not provide an assessment of results in the context of global benchmarks or comparable companies.
Management Changes
| Role | Previous Person | New Person | Effective Date | Reason |
|---|---|---|---|---|
| NA | NA | NA | NA | NA |
Corporate Governance
| Change Type | Description | Effective Date | Impact Assessment |
|---|---|---|---|
| NA | NA | NA | NA |
Legal Proceedings
- NA This filing does not report any litigation or regulatory matters for Inhibrx Biosciences, Inc.
Related Party Transactions
- NA This filing does not disclose any related party dealings for Inhibrx Biosciences, Inc.
Stakeholder Impact
- Shareholders: May interpret the reduction in BlackRock's stake as a signal of decreased institutional confidence, potentially influencing stock price.
Next Steps
- NA This filing does not mention any future actions, events, or milestones for Inhibrx Biosciences, Inc.
Key Dates
| Date | Description |
|---|---|
| 2025-01-21 | Date of execution of the Power of Attorney by BlackRock, Inc. |
| 2025-09-30 | Date of event which required the filing of this statement, indicating BlackRock's ownership position. |
| 2025-10-17 | Date of signature for the Schedule 13G filing by BlackRock, Inc. |
Recommendation
holdBlackRock, a major institutional investor, has reduced its stake in Inhibrx Biosciences, Inc. to below 5%. While this is not a complete divestment, the reduction below a key reporting threshold can be interpreted as a signal of decreased conviction or a strategic reallocation of capital. For a seasoned investor, this suggests a cautious approach, warranting a 'hold' recommendation to observe further developments rather than an immediate 'buy' or 'sell' unless other fundamental factors are strongly compelling.
Keywords
Inhibrx Biosciences, BlackRock, Schedule 13G, beneficial ownership, common stock, institutional investor, equity stake, 45720N103
Disclaimer:The information provided here is for general informational purposes only and does not constitute financial advice, recommendation, or endorsement of any kind. It may contain errors or omissions. You should not rely on this information to make financial decisions. Always seek the advice of a qualified financial professional before making any investment or financial decisions. Use of this information is at your own risk.